LivaNova PLC
LIVN: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| pHz | LOCK|@#DYL | LOCK|xk |
Livanova Earnings: Strength in 2025 Leaves Firm Poised for Favorable 2026
Livanova reported revenue growth of 10% (in constant currency) for both the fourth quarter and full-year 2025. This was fueled by 13% and 7% increases in cardiopulmonary and neuromodulation revenue in 2025, respectively.
